Home › Funds › Bollard Group LLC › ABT

Bollard Group LLC position in ABT

ABBOTT LABORATORIES · Health Care

Bollard Group LLC reported holding 74,516 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$7.4M, representing 0.32% of its reported portfolio and ranking #49 among its reported holdings. Bollard Group LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)74.52K sh
Reported value held$7.36M
Portfolio Weight0.32%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Bollard Group LLC's ABT position evolved

Bollard Group LLC first disclosed a stake in ABT in Q3 2023 at 92,273 shares (US$8.9M). The position peaked in Q3 2025 at 94,289 shares, worth US$12.6M. Across 13 filings, Bollard Group LLC increased the stake 7 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 74,516 shares valued at US$7.4M — a reduction of -6,409 shares quarter over quarter.. Notable position changes include a 27% trim in Q4 2025 (shares fell 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 92.27K $8.94M New
Q4 2023 97.91K $10.78M Add
Q1 2024 98.63K $11.21M Add
Q2 2024 100.18K $10.41M Add
Q3 2024 100.62K $11.47M Hold
Q4 2024 85.44K $9.66M Reduce
Q1 2025 85.78K $11.38M Hold
Q2 2025 90.80K $12.35M Add
Q3 2025 94.29K $12.63M Add
Q4 2025 68.57K $8.59M Reduce
Q1 2026 79.77K $8.19M Add
Q2 2026 80.92K $7.34M Add
Q3 2026 74.52K $7.36M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Bollard Group LLC held ABT?

Bollard Group LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Bollard Group LLC's current position in ABT?

As of Q3 2026, Bollard Group LLC holds 74.52K shares of ABT (ABBOTT LABORATORIES), valued at $7.36M, representing 0.32% of its reported portfolio and ranking #49.

Has Bollard Group LLC been buying or selling ABT?

In the latest 13F filing (Q3 2026), Bollard Group LLC reduced its position in ABT. The position peaked in Q3 2025 at 94.29K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.